Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04297683 · ClinicalTrials.gov registry record · Phase 2

HEALEY ALS Platform Trial - Master Protocol

A Phase 2 study of Amyotrophic Lateral Sclerosis, sponsored by Merit E. Cudkowicz, MD.

Recruiting
Registry status
Phase 2
Development phase
1,500
Enrollment target
20
Study locations

NCT04297683 is a Phase 2 study of Amyotrophic Lateral Sclerosis that is actively recruiting participants, run by Merit E. Cudkowicz, MD. The registered enrollment target is 1,500 participants, above the 883-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (70% higher). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04297683, a Phase 2 study of Amyotrophic Lateral Sclerosis, is actively recruiting participants, sponsored by Merit E. Cudkowicz, MD.

RECRUITING
Registry status
Phase 2
Development phase
1,500 participants
Enrollment target
20
Study locations

Study Summary

The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.

Conditions Studied

Amyotrophic Lateral Sclerosis

Interventions

  • DRUG Zilucoplan
  • DRUG Verdiperstat
  • DRUG CNM-Au8
  • DRUG Pridopidine
  • DRUG SLS-005 Trehalose

Study Locations (20)

California

  • Loma Linda University Health - Loma Linda
  • Kaiser Permanente Los Angeles Medical Center - Los Angeles
  • University of Southern California - Los Angeles
  • Cedars-Sinai Medical Center - Los Angeles
  • University of California, Irvine - Orange
  • Forbes Norris MDA/ALS Research Center, California Pacific Medical Center - San Francisco
  • University of California, San Francisco - San Francisco

Florida

  • Nova Southeastern University - Davie
  • University of Florida - Gainesville
  • Mayo Clinic Florida - Jacksonville
  • University of Miami - Miami
  • University of South Florida - Tampa

Arizona

  • Barrow Neurological Institute - Phoenix
  • Mayo Clinic Scottsdale - Scottsdale

Connecticut

  • Hospital for Special Care - New Britain
  • Yale University - New Haven

District of Columbia

  • Georgetown University - Washington D.C.
  • George Washington University - Washington D.C.

Arkansas

  • University of Arkansas for Medical Sciences - Little Rock

Colorado

  • University of Colorado - Aurora

Trial Details

FieldValue
Enrollment Target 1,500 participants
Start Date 2020-06-14
Est. Completion 2028-08
Phase Phase 2

Sponsor

Merit E. Cudkowicz, MD

8 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04297683

The ClinicalTrials.gov registry entry for NCT04297683 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 1,500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 883-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (70% higher). The listed sponsor is Merit E. Cudkowicz, MD, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Amyotrophic Lateral Sclerosis appearing as the primary indexed condition, and to 5 interventions - of which Zilucoplan is the first listed.

NCT04297683 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Arizona.

Frequently Asked Questions

What is clinical trial NCT04297683 about?

NCT04297683 is a clinical study titled "HEALEY ALS Platform Trial - Master Protocol". The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.

What is the current status of trial NCT04297683?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 1,500 participants. The study started on 2020-06-14. Estimated completion is 2028-08.

What conditions does trial NCT04297683 study?

This clinical trial studies the following conditions: Amyotrophic Lateral Sclerosis.

What interventions are being tested in trial NCT04297683?

The interventions under investigation include: Zilucoplan (DRUG), Verdiperstat (DRUG), CNM-Au8 (DRUG), Pridopidine (DRUG), SLS-005 Trehalose (DRUG).

Who is sponsoring clinical trial NCT04297683?

This trial is sponsored by Merit E. Cudkowicz, MD, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04297683 being conducted?

This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Amyotrophic Lateral Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Amyotrophic Lateral Sclerosis

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.